Hirudin-Like Factors (HLFs)
Hirudin-paralog family lacking some structural hirudin features — Müller 2016 phylogenetic characterization across Hirudo and Hirudinaria genera.
Preclínico / mecanísticoLast updated: 2026-05-27 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Hirudin-paralog family lacking some structural hirudin features — Müller 2016 phylogenetic characterization across Hirudo and Hirudinaria genera.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
HLFs are characterized phylogenetically; their molecular targets are not yet established. No FDA-approved derivative exists; do not extrapolate hirudin clinical activity to HLFs.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 7,000 Da
- Source species
- Hirudo medicinalis / Hirudo verbana / Hirudinaria manillensis
- Discovered
- 2016 · Müller C et al.
Biological Targets
- → unknown / putative thrombin or other coagulation factors
Key Citations
- Müller C et al. (2016), Parasitol Res · PMID 27785600
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.